Reuters: Regulatory News: US FDA gives nod to Forest/Almirall lung drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

US FDA gives nod to Forest/Almirall lung drug Jul 23rd 2012, 18:45 WASHINGTON, July 23 | Mon Jul 23, 2012 2:45pm EDT WASHINGTON, July 23 (Reuters) - U.S. drug regulators gave the nod to Forest Laboratories Inc's inhaled treatment for smoker's cough, boosting the company's plans to prop up profits with a new crop of medicines. The Food and Drug Administration approved the twice-daily drug, to be sold as Tudorza Pressair, to treat symptoms of chronic obstructive pulmonary disease (COPD), a serious lung disease that makes breathing difficult and is often caused by cigarette smoking. It is the fourth-leading killer of Americans. Forest developed the drug with Spanish company Almirall SA and will market it in the United States.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions